BPC-157
Injury, Repair & RecoveryPreclinicalAlso known as: Body Protection Compound, Pentadecapeptide, BPC, Repair Balm
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC. It has a molecular weight of 1419.53 Da and a CAS number of 137525-51-0.
Reconstitution Calculator for BPC-157
Pre-filled · 5mg vial · 250mcg dose
Overview
At A Glance
Nitric Oxide (NO) System Modulation…
Overview
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC. It has a molecular weight of 1419.53 Da and a CAS number of 137525-51-0. BPC-157 is classified as a stable gastric pentadecapeptide because it resists hydrolysis by gastric acid and digestive enzymes, a property that differentiates it from most bioactive peptides and enables oral bioavailability in preclinical models (PMID: 21524250). As of 2026, BPC-157 has been investigated in more than 90 published preclinical studies spanning models of gastrointestinal injury, tendon and ligament damage, nerve injury, wound healing, and organ protection. A complete review by Sikiric et al. (2011) established BPC-157 as a peptide with broad cytoprotective and regenerative properties across multiple organ systems (PMID: 21524250). Subsequent work by Seiwerth et al. (2022) expanded the evidence base to include vascular protection and modulation of the nitric oxide (NO) system as a central integrative mechanism (PMID: 36416831). BPC-157 is not approved by the United States Food and Drug Administration (FDA) for any therapeutic indication. It is classified under the World Anti-Doping Agency (WADA) Prohibited List category S0 (non-approved substances), making it banned in competitive sport. Despite the lack of regulatory approval, BPC-157 is widely used in the research peptide and biohacking communities, primarily administered via subcutaneous injection or oral capsule for musculoskeletal recovery and gut healing. Preclinical studies have demonstrated that BPC-157 accelerates healing of transected rat Achilles tendons, with treated animals showing superior biomechanical tendon strength at 14 days post-injury compared to controls (PMID: 30915550). In gastrointestinal models, BPC-157 has shown protective effects against NSAID-induced gastric lesions, ethanol-induced mucosal damage, and inflammatory bowel disease (IBD) analogs including experimentally induced colitis (PMID: 29898088). The peptide has also demonstrated neuroprotective activity in dopaminergic and serotonergic systems, counteracting lesions caused by neurotoxins in rodent models (PMID: 21524250). A 2025 pilot safety study by Lee et al. represents the first published human intravenous (IV) administration data for BPC-157. In this small cohort, IV BPC-157 was administered at escalating doses with no serious adverse events reported and no clinically significant changes in laboratory parameters (PMID: 40131143). While this study was not powered to establish efficacy, it provided the first formal human safety signal for the peptide. BPC-157 has also been shown to upregulate growth hormone receptor (GHR) expression in animal models, suggesting a possible synergistic effect when combined with growth hormone secretagogues (PMID: 30175840). The peptide is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Lyophilized BPC-157 should be stored at -20 degrees Celsius in a desiccated environment; once reconstituted, it should be refrigerated at 2-8 degrees Celsius and used within 28 days to maintain peptide integrity.
Potential Research Fields
Chemical Information
IUPAC Name
L-valyl-L-lysyl-L-alanyl-L-arginyl-L-leucyl-L-histidyl-L-glycyl-L-lysyl-L-prolyl-L-alanyl-L-glycyl-L-glycyl-L-prolyl-L-prolyl-L-proline
CAS Number
137525-51-0
Molecular Formula
C62H98N16O22
Molecular Mass
1419.56 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Active cancer or history of cancer (due to angiogenic properties). Pregnancy or breastfeeding. Concurrent use of anticoagulants (may affect platelet function). Caution in patients with active infections where increased blood flow could spread pathogens.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$29.00
up to $90.00
$0.1600
8
19
vial, topical, capsule
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
BPC-157 Capsules | capsule | 60 caps (500mcg each)● In Stock | $79.99BEST | $0.160 | ||
|
|
BPC-157 Capsules 60ct | capsule | 60 capsules● In Stock | $79.99 | $2.666 | ||
 |
BPC-157 10mg | vial | 5mg● In Stock | $37.99 | $3.799 | ||
 |
BPC-157 5mg | vial | 1 vial● Out of Stock | $29.00 | $5.800 | — | Sign in for stock alert |
|
|
BPC-157 10mg | vial | 1 vial● In Stock | $48.00 | $4.800 | — | |
|
|
BPC-157 20mg | vial | 1 vial● Out of Stock | $85.00 | $4.250 | — | Sign in for stock alert |
| Detox Balm | topical | 0mg● In Stock | $65.00 | — | |||
| Repair Balm | topical | 0mg● In Stock | $90.00 | — | |||
 |
BPC-157 5mg | vial | 1 vial● In Stock | $34.99 | $6.998 | — | |
|
|
BPC-157 5mg | vial | 1 vial● In Stock | $34.99 | $6.998 | — | |
|
|
BPC-157 10mg | vial | 1 vial● In Stock | $49.99 | $4.999 | — | |
|
|
BPC-157 10mg | vial | 1 vial● In Stock | $54.99 | $5.499 | — | |
 |
BPC-157 5mg Vial | vial | 1 vial● In Stock | $35.00 | $7.000 | ||
|
|
BPC-157 10mg Vial | vial | 1 vial● In Stock | $65.00 | $6.500 | ||
|
|
BPC-157 500mcg Capsules | capsule | 1 bottle● In Stock | $75.00 | $150.000 | ||
 |
BPC-157 10mg | vial | 1 vial● Out of Stock | $53.50 | $5.350 | Sign in for stock alert | |
|
|
BPC-157/TB-500 5+5mg | vial | 1 vial● In Stock | $69.99 | $6.999 | ||
 |
BPC-157 5mg | vial | 5mg vial● In Stock | $34.99 | $6.998 | ||
|
|
BPC-157 10mg | vial | 10mg vial● In Stock | $54.99 | $5.499 |
Tracking since Mar 13, 2026 · 15 data points
Price History
6 data pointsVendors Selling BPC-157
Ion Peptide
BioMyst Labs
VANDL Labs
Nova Peptides
Optimum Formula
Limitless Biochem EU
Adera
ResearchChemHQ
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for BPC-157
Related Articles
All PostsAquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works For
how aquasome 3-layer nano-encapsulation lets peptides like retatrutide, bpc-157, and tb-500 survive the gut. pubmed-backed deep dive on the 10 compounds it works for.
5/20/2026Retatrutide Protocol Guide 2026: Dosing, Titration, Side Effects, Week-by-Week
A standalone beginner protocol for retatrutide — Eli Lilly's triple GLP-1/GIP/glucagon agonist. Dose math, week-by-week titration, side-effect management, realistic expectations, and where to source research-grade material.
5/19/2026Tirzepatide to Retatrutide Switch Protocol — A Data-Driven Crossover Guide (2026)
How to cross-titrate from tirzepatide (Mounjaro/Zepbound) to retatrutide safely. The 2-3 week hold + titration ladder, what bloodwork to track, when the switch makes sense, and when to stay on tirzepatide.
5/18/2026Research Score
214 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Well-researched compound
Quick Facts
Half-Life
~4 hours (estimated from animal pharmacokinetic data)
Molecular Weight
1419.56 g/mol
Administration
Subcutaneous, Oral, Intraperitoneal, Intravenous
CAS Number
137525-51-0
Trial Phase
Preclinical
Safety Profile
Common Side Effects
- • Injection site redness or mild irritation (subcutaneous)
- • Mild nausea with oral administration (rare)
- • Transient lightheadedness reported anecdotally
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
The Wolverine Stack: BPC-157 + TB-500 Protocol Guide
Complete synergistic recovery protocol — dosing tables, cycling, reconstitution, and 9 PubMed citations.
Frequently Asked Questions
What is BPC-157 used for in research?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC. It has a molecular weight of 1419.53 Da and a CAS number of 137525-51-0. BPC-157 is classified as a stable gastric pentadecapeptide because it resists hydrolysis by gastric acid and digestive enzymes, a property that differentiates it from most bioactive peptides and enables oral bioavailability in preclinical models (PMID: 21524250).
As of 2026, BPC-157 has been investigated in more than 90 published preclinical studies spanning models of gastrointestinal injury, tendon and ligament damage, nerve injury, wound healing, and organ protection. A complete review by Sikiric et al. (2011) established BPC-157 as a peptide with broad cytoprotective and regenerative properties across multiple organ systems (PMID: 21524250). Subsequent work by Seiwerth et al. (2022) expanded the evidence base to include vascular protection and modulation of the nitric oxide (NO) system as a central integrative mechanism (PMID: 36416831).
BPC-157 is not approved by the United States Food and Drug Administration (FDA) for any therapeutic indication. It is classified under the World Anti-Doping Agency (WADA) Prohibited List category S0 (non-approved substances), making it banned in competitive sport. Despite the lack of regulatory approval, BPC-157 is widely used in the research peptide and biohacking communities, primarily administered via subcutaneous injection or oral capsule for musculoskeletal recovery and gut healing.
Preclinical studies have demonstrated that BPC-157 accelerates healing of transected rat Achilles tendons, with treated animals showing superior biomechanical tendon strength at 14 days post-injury compared to controls (PMID: 30915550). In gastrointestinal models, BPC-157 has shown protective effects against NSAID-induced gastric lesions, ethanol-induced mucosal damage, and inflammatory bowel disease (IBD) analogs including experimentally induced colitis (PMID: 29898088). The peptide has also demonstrated neuroprotective activity in dopaminergic and serotonergic systems, counteracting lesions caused by neurotoxins in rodent models (PMID: 21524250).
A 2025 pilot safety study by Lee et al. represents the first published human intravenous (IV) administration data for BPC-157. In this small cohort, IV BPC-157 was administered at escalating doses with no serious adverse events reported and no clinically significant changes in laboratory parameters (PMID: 40131143). While this study was not powered to establish efficacy, it provided the first formal human safety signal for the peptide.
BPC-157 has also been shown to upregulate growth hormone receptor (GHR) expression in animal models, suggesting a possible synergistic effect when combined with growth hormone secretagogues (PMID: 30175840). The peptide is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Lyophilized BPC-157 should be stored at -20 degrees Celsius in a desiccated environment; once reconstituted, it should be refrigerated at 2-8 degrees Celsius and used within 28 days to maintain peptide integrity.
What forms does BPC-157 come in?
BPC-157 is available in vial, topical, capsule forms.
How much does BPC-157 cost?
Prices start at $29.00 across 8 verified vendors.
How do I compare BPC-157 vendors?
Compare prices, payment methods, shipping, and COA scores across 8 vendors.
Research Tools
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsCompare BPC-157 head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.